Measured Wealth Private Client Group LLC increased its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 1.5% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,348 shares of the company’s stock after purchasing an additional 78 shares during the quarter. Measured Wealth Private Client Group LLC’s holdings in Johnson & Johnson were worth $885,000 as of its most recent SEC filing.
Other large investors have also added to or reduced their stakes in the company. BlackRock Inc. raised its position in Johnson & Johnson by 1.4% during the first quarter. BlackRock Inc. now owns 201,491,567 shares of the company’s stock worth $31,231,193,000 after acquiring an additional 2,688,798 shares in the last quarter. Moneta Group Investment Advisors LLC raised its position in shares of Johnson & Johnson by 90,144.4% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock valued at $9,607,414,000 after purchasing an additional 54,326,454 shares during the period. Geode Capital Management LLC raised its position in shares of Johnson & Johnson by 1.6% in the first quarter. Geode Capital Management LLC now owns 48,707,500 shares of the company’s stock valued at $7,532,525,000 after purchasing an additional 748,917 shares during the period. Morgan Stanley raised its position in shares of Johnson & Johnson by 12.0% in the fourth quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock valued at $7,458,962,000 after purchasing an additional 4,521,062 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its position in shares of Johnson & Johnson by 15.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 29,277,774 shares of the company’s stock valued at $5,171,919,000 after purchasing an additional 3,849,148 shares during the period. Institutional investors and hedge funds own 68.40% of the company’s stock.
Analyst Upgrades and Downgrades
Several equities analysts recently commented on the stock. Morgan Stanley decreased their price target on shares of Johnson & Johnson from $187.00 to $172.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 31st. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Friday, September 29th. Atlantic Securities increased their price objective on shares of Johnson & Johnson from $167.00 to $170.00 and gave the stock a “neutral” rating in a research note on Friday, August 4th. Royal Bank of Canada initiated coverage on shares of Johnson & Johnson in a research note on Wednesday, October 4th. They set an “outperform” rating and a $178.00 price objective on the stock. Finally, TheStreet upgraded shares of Johnson & Johnson from a “c+” rating to a “b+” rating in a research note on Monday, August 21st. Nine equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average target price of $171.06.
Insiders Place Their Bets
In other Johnson & Johnson news, insider William Hait sold 14,698 shares of the firm’s stock in a transaction that occurred on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the completion of the transaction, the insider now owns 87,747 shares in the company, valued at approximately $15,092,484. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, VP Peter Fasolo sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the completion of the sale, the vice president now owns 102,696 shares of the company’s stock, valued at approximately $17,491,182.72. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider William Hait sold 14,698 shares of the firm’s stock in a transaction that occurred on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the sale, the insider now directly owns 87,747 shares of the company’s stock, valued at approximately $15,092,484. The disclosure for this sale can be found here. Company insiders own 0.20% of the company’s stock.
Johnson & Johnson Stock Up 0.3 %
Shares of NYSE JNJ opened at $157.64 on Monday. The company has a 50 day simple moving average of $164.30 and a 200 day simple moving average of $162.40. The firm has a market cap of $409.70 billion, a PE ratio of 31.91, a price-to-earnings-growth ratio of 3.19 and a beta of 0.55. Johnson & Johnson has a 1 year low of $150.11 and a 1 year high of $181.04. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.12 and a quick ratio of 0.88.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its quarterly earnings data on Thursday, July 20th. The company reported $2.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.62 by $0.18. The business had revenue of $25.53 billion during the quarter, compared to analyst estimates of $24.63 billion. Johnson & Johnson had a net margin of 13.35% and a return on equity of 36.72%. The firm’s quarterly revenue was up 6.3% on a year-over-year basis. During the same quarter last year, the business earned $2.59 EPS. On average, research analysts forecast that Johnson & Johnson will post 10.02 EPS for the current year.
Johnson & Johnson Announces Dividend
The company also recently declared a quarterly dividend, which was paid on Thursday, September 7th. Shareholders of record on Monday, August 28th were issued a dividend of $1.19 per share. The ex-dividend date of this dividend was Friday, August 25th. This represents a $4.76 annualized dividend and a yield of 3.02%. Johnson & Johnson’s payout ratio is 96.36%.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Read More
- Five stocks we like better than Johnson & Johnson
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- How To Find Value Stocks Using This Simple Filtering Method
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- MarketBeat Week in Review – 10/2 – 10/6
- How to Buy Gold Stock and Invest in Gold
- Levi Strauss: A Bottom is in for Steady, Stable Dividend Payer
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
